Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2CLIMB-02: tucatinib or placebo plus T-DM1 in advanced HER2-positive breast cancer
NL-OMON51919Phase 3Completed
- Sponsor
- Seagen Inc.
- Start
- Jul 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tucatinib and trastuzumab emtansine in breast cancer (2 arms), sponsored by Seagen Inc. Primary endpoint: Progression-free survival by investigator assessment. Started Jul 2021; status: completed.
02
Drugs
tucatinibtrastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON51919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51919.